ERCC1 and cancer: Based on the above discussion, we propose that this inhibitor has the following advantages: (1) suppression of the function of ERCC1–XPF, which is very important to increase the chemotherapy and radiotherapy in cancer; (2) the XPF–ERCC1 blocker may be used widely in the treatment of many different cancers; (3) ERCC1 has low toxicity and is a safe target.